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OBJECTIVES: Ticagrelor is a reversibly binding oral P2Y12-receptor antagonist de-
veloped for reduction of thrombosis. The PLATO trial compared ticagreloraspirin
to clopidogrelaspirin in individuals with acute coronary syndromes (ACS); ti-
cagrelor was superior on the primary composite endpoint of cardiovascular death,
myocardial infarction (MI) or stroke, without an increase in major bleeding events.
The current study estimates the lifetime cost-effectiveness of ticagrelor relative to
generic clopidogrel fromaSingapore public health care perspective.METHODS: For
the analysis of cost-effectiveness, a two-part cost-effectiveness model was used.
The first part was a 12-month decision tree using PLATO trial data to estimate rates
ofmajor cardiovascular events, health care costs, and health-related quality of life.
The second part was a Markovmodel estimating lifetime quality-adjusted survival
and costs conditional on whether a non-fatal MI, a non-fatal stroke, or no MI or
stroke occurred during the initial 12 months. The model applied a lifetime horizon
to calculate mean direct medical costs and QALYs. The results are presented as
incremental cost-effectiveness ratios (ICER’s). Daily costs of SGD1.10 for generic
clopidogrel and SGD6.00 for ticagrelorwere applied.We calculated short term costs
by applying Singapore unit costs, and costs from a comparable Asian country (Ko-
rea) to derive the Markov costs. Probabilistic sensitivity analysis was performed.
RESULTS: Ticagrelor was associated with a lifetime QALY gain of 0.13, primarily
driven by lower cardiovascular mortality. The resulting incremental cost per QALY
gained was SGD10,136 from the public sector perspective. Probabilistic sensitivity
analysis indicated that ticagrelor had more than 99% probability of being cost-
effective given the recommended WHO willingness to pay threshold of one GDP/
capita or SGD56,000 per QALY. CONCLUSIONS: Based on the PLATO trial data, one
year treatment with ticagreloraspirin versus generic clopidogrelaspirin in ACS
patients, relative to WHO reference standards, is cost-effective from a Singapore
public health care perspective.
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OBJECTIVES:To estimate the long-time cost-effectiveness of Left Atrial Appendage
(LAA) occlusion device for preventing stroke in a hypothetical cohort of 65-year-old
patientswith atrial fibrillation (AF).METHODS:Adecision analyticmodel was used
to perform a cost-effectiveness analysis comparing LAA occlusion device and 5
alternative anticoagulant therapies from a health care provider perspective. Treat-
ment strategies for AF are included Aspirin, dual therapy with Aspirin and Clopi-
dogrel, Warfarin, Dabigatran 150mg or 110mg, and LAA occlusion device. The pa-
rameters including rate of adverse events, utility, and costs were derived from the
ACTIVE trial, RE-LY trial, PROTECT trial, and published references in our model.
Outcomes are quality-adjusted life years (QALYs), lifetime costs, and incremental
cost-effectiveness ratios (ICERs). Costs and QALYs were discounted at an annual
rate of 3%. One way sensitivity varied by the CHADS2score and probabilistic sen-
sitivity analyses (PSAs)were conducted to assess parameter uncertainty. RESULTS:
Compared with Aspirin, LAA occlusion device, Warfarin, Dabigatran 150mg and
110mg were cost-effective. The ICERs were US$975 per QALY with LAA occlusion
device, US$4,982 per QALY with Warfarin, US $10,672 per QALY with Dabigatran
150mg, US$10,972 per QALY with Dabigatran 110mg. When using Warfarin as a
comparator, LAA occlusion device is less costly and more effective, Dabigatran
150mg cost US$28,556 per QALY, and Dabigatran 110mg cost UD$37,328 per QALY.
For patient with CHADS2 score of 0, 1, 2, 3, or 3a4, the ICREs of LAA occlusion device
over Aspirin were US$1,257 per QALY, US$1,104 per QALY, US$894 per QALY,
US$626 per QALY, US$518 per QALY, respectively. LAA occlusion device was cost-
effective over 95% of theMonte Carlo simulation using a cost-effectiveness thresh-
old of US$50,000 per QALY.CONCLUSIONS:The LAA occlusion device is considered
cost-effective compared with Aspirin, Warfarin, Dabigatran 150mg or 110mg in AF
patients.
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OBJECTIVES: To estimate the cost-effectiveness of delayed troponin testing for
myocardial infarction (MI), as recommended in current guidelines, compared to
troponin testing and other biomarkers at presentation.METHODS:Wedeveloped a
decision analytic model to estimate the cost-effectiveness of diagnostic strategies
for MI, measured as the incremental cost per quality-adjusted life year (QALY)
gained by each strategy compared to the nextmost effective alternative. Themodel
was applied to a hypothetical population of 1000 patients attending hospital with
symptoms suggesting MI but a normal or non-diagnostic electrocardiogram (ECG)
and no major co-morbidities requiring hospital treatment. Sensitivity and speci-
ficity of the strategieswere estimated bymeta-analysis of diagnostic cohort studies
of presentation troponin T. The risk of reinfarction and death (with and without
treatment) was determined using data from a study by Mills et al, Lifetime QALYs
were estimated from life expectancy and corresponding annual utilities. The dis-
counted life expectancy of patientswithMI andMIwith reinfarctionwas estimated
from Polanczyk et al, while the utility of patients withMIwas estimated fromWard
et al. RESULTS: In all scenarios tested presentation high sensitivity troponin test-
ing was the most effective strategy with an incremental cost-effectiveness ratio
(ICER) below the £20,000/QALY threshold. Delayed troponin testing was only likely
to be cost-effective if a discharge decision could be made as soon as a negative
result was available and the £30,000/QALY threshold was used. CONCLUSIONS:
Delayed troponin testing is unlikely to be cost-effective compared to high sensitiv-
ity troponin testing at presentation in most scenarios. Current guidelines recom-
mending 10-12 hour troponin testing does not appear to promote cost-effective use
of hospital resources, unless services are in place to allow rapid decision making
once delayed test results are available.
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OBJECTIVES: The PLATO trial showed that ticagrelor significantly reduced the rate
of cardiovascular mortality, myocardial infarction, or stroke compared to clopi-
dogrel in patients with acute coronary syndrome (ACS) with additional drug cost.
Critical appraisal is necessarily important to justify adopting this new treatment in
the era of limited health care resources. This study aimed to evaluate long-term
cost-effectiveness of ticagrelor plus acetylsalicylic acid (ASA) versus clopidogrel
plus ASA in ACS patients in Thailand. METHODS: A two-part decision-analytic
model, comprising a one-year decision tree and a long-term Markov model, was
constructed to estimate lifetime costs and quality-adjusted life years (QALYs) from
Thai health care payer’s perspective. For the first year, data from PLATOwere used
to estimate rate of cardiovascular events, resource use, and QALYs. For year two
and onwards, clinical effectivenesswas estimated conditional on individual health
states occurred during the first year. Unit costs were based on Thai database. All
costs presented in year 2011 and effects were discounted at 3% per annum. A series
of sensitivity analyses were performed to assess robustness of the model.
RESULTS: The incremental cost -effectiveness ratios (ICERs) with ticagrelor were
312,044 and 79,979 THB/QALY compared to generic and branded clopidogrel, re-
spectively. Probabilistic sensitivity analysis indicated that ticagrelor has high prob-
abilities of being cost effective compared to generic (85.0%) and branded clopi-
dogrel (99.9%) at a willingness to pay threshold of 3 times GDP/capita.
CONCLUSIONS: It might be appropriate to assert that ticagrelor is an economically
valuable treatment of ACS within the Thai context.
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Peripheral arterial disease (PAD) is a condition in which there is blockage or nar-
rowing of the arteries that carry blood to the peripheries. Themost common symp-
tom of PAD is intermittent claudication (IC), characterised by pain in the legs on
walking that is relieved with rest. Symptoms of IC can be managed with exercise
therapy and/or vasoactive drugs. OBJECTIVES: To assess the cost-effectiveness of
the vasoactive drugs cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol
nicotinate for IC due to PAD in adultswhose symptoms continue despite a period of
conservativemanagement.METHODS:AMarkov decisionmodel was developed to
assess the lifetime costs and benefits of each vasoactive drug compared with no
vasoactive drug andwith each other. Regression analysiswas undertaken tomodel
the relationship betweenmaximumwalking distance and utility based on patient-
level data from a trial of cilostazol to enable quality of life impacts to be estimated
for the other drugs under consideration. Resource use data were sourced from the
literature and a comprehensive sensitivity analysiswas undertaken.RESULTS:The
economic evaluation suggests that naftidrofuryl oxalate is more effective and less
costly than cilostazol and pentoxifylline and has an estimated cost per QALY
gained of around £6070 compared with no vasoactive drug. Whilst there is limited
effectiveness evidence associated with inositol nicotinate, threshold analysis sug-
gests that it is unlikely to be considered to be cost-effective due to its more expen-
sive acquisition cost.CONCLUSIONS:This is the first published cost-utility analysis
in this areawhich extrapolates data over a lifetime and uses effectiveness evidence
from a network meta-analysis. In contrast to previous guidelines recommending
cilostazol, this comprehensive analysis suggests that naftidrofuryl oxalate is the
only vasoactive drug for PAD which is likely to be cost-effective at a willingness to
pay threshold of £20,000 per QALY gained.
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OBJECTIVES: To evaluate the cost-effectiveness of apixaban versus enoxaparin in
the prevention of venous thromboembolism (VTE) after total hip replacement
(THR) and total knee replacement (TKR) from the perspective of the Korean health
care system.METHODS:Adecision treemodel was developed to simulate the costs
and outcomes of VTE prevention, and consisted of 3 phases- 1) prophylaxis phase;
2) post-prophylaxis phase (up to 90 days); and 3) long-termcomplications phase (up
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